C

Climb Bio Inc
D

CLYM

12.777
USD
0.20
(1.57%)
مغلق
حجم التداول
0
الربح لكل سهم
-1
العائد الربحي
-
P/E
-17
حجم السوق
731,649,645
المقالات
المزيد

العنوان: Climb Bio Inc

القطاع: Healthcare
الصناعة: Biotechnology
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.